Significant Shareholders

As at 23 January 2023, shareholders holding more than 3% of the share capital of Tissue Regenix Group Plc are:

Name of Shareholder Number of Shares % of Voting Rights
Harwood Capital (London) 1,104,500,000 15.70
Mr Richard Griffiths (UK) 775,369,000 11.02
Inthallo Limited 783,952,500 11.14
Lombard Odier 654,299,634 9.30
IP Group (London) 653,042,837 9.28

Board of Directors

Name of Shareholder Number of Shares % of Voting Rights
Jonathan Glenn, Chair 40,600,000 0.58
Brian Phillips, Non-Executive Director  15,322,756 0.22
Daniel Lee, Chief Executive Officer  7,262,200 0.10
David Cocke, Chief Financial Officer 5,692,000 0.08

Trevor Phillips, Non-Executive Director
5,535,771 0.08
Shervanthi Homer-Vanniainkam, Non-Executive Director  1,628,222 0.02

Shares not in public hands as at 23 January 2023 - 3,272,981,199 - 46.52%

Shares in issue as at 23 January 2023 - 7,035,794,890 ordinary shares of 0.1p each

The securities of Tissue Regenix Group plc are traded on the AIM market operated by the London Stock Exchange plc. Its shares have not been admitted, nor have any applications been made, for any of its shares to be admitted or traded on any other exchanges or trading platform.

Key Advisors

You may also be interested in